ADVANCED MEDICAL OPTICS INC

Form SC 13D/A June 05, 2007

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities and Exchange Act of 1934

(Amendment No. 1)

Advanced Medical Optics, Inc.

(Name of Issuer)

Common Stock, \$0.01 par value per share

(Title of Class of Securities)

00763M108

(CUSIP Number)

Allison Bennington, Esq.
ValueAct Capital
435 Pacific Avenue, Fourth Floor
San Francisco, CA 94133
(415) 362-3700

(---)

(Name, address and telephone number of Person Authorized to Receive Notices and Communications)

Christopher G. Karras, Esq.

Dechert LLP

Cira Centre

2929 Arch Street

Philadelphia, PA 19104-2808

(215) 994-4000

May 29, 2007

<u>-</u>

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [].

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 240.13d-7 for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

This information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of

the Act but shall be subject to all other provisions of the Act (however, see

the Notes). ______ SCHEDULE 13D CUSIP NO. 00763M108 Page 2 of 19 1. NAME OF REPORTING PERSON/S.S. OR I.R.S. INDENTIFICATION NO. OF ABOVE PERSON (entities only) ValueAct Capital Master Fund, L.P. _____ 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [X] ______ 3. SEC USE ONLY 4. SOURCE OF FUNDS (See Instructions) * WC* ______ 5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ______ 6. CITIZENSHIP OR PLACE OF ORGANIZATION British Virgin Islands 7. SOLE VOTING POWER 0 NUMBER OF _____ 8. SHARED VOTING POWER SHARES BENEFICIALLY 5,298,830** OWNED BY EACH 9. SOLE DISPOSITIVE POWER PERSON WITH 10. SHARED DISPOSITIVE POWER 5,298,830** 11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,298,830** _____ 12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ______ 13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) ______ 14. TYPE OF REPORTING PERSON _____ *See Item 3

**See Item 2 and 5

SCHEDULE 13D

CUSIP NO. 00763M108	3	Page 3 of 1	
1. NAME OF REPORTIN	IG PERSON/S.S. OR I.R.S. INDENTIFICATION NO. s only)	OF ABOVE	
ValueAct Capital	Master Fund III, L.P.		
2. CHECK THE APPRO	PRIATE BOX IF A MEMBER OF A GROUP*	(a) [(b) [-
3. SEC USE ONLY			
4. SOURCE OF FUNDS	(See Instructions)*		
WC*			
5. CHECK BOX IF DIS	SCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED AS 2(d) or 2(e)		.]
6. CITIZENSHIP OR I	LACE OF ORGANIZATION		
British Virgin	slands		
NUMBER OF	7. SOLE VOTING POWER 0		
BENEFICIALLY	8. SHARED VOTING POWER 612,805**		
OWNED BY EACH PERSON WITH	9. SOLE DISPOSITIVE POWER 0		
	10. SHARED DISPOSITIVE POWER 612,805**		
11. AGGREGATE AMOUN	IT BENEFICIALLY OWNED BY EACH REPORTING PERS	 ON	
612,805**			
12. CHECK BOX IF THE CERTAIN SHARES	HE AGGREGATE AMOUNT IN ROW (11) EXCLUDES		.]
13. PERCENT OF CLAS	SS REPRESENTED BY AMOUNT IN ROW (11)		
	TNG PERSON		
PN	INO I EMOON		
	SCHEDULE 13D		
CUSIP NO. 00763M108		 Page 4 of 1	

1. NAME OF REPORTING PERSON/S.S. OR I.R.S. INDENTIFICATION NO. OF ABOVE

PERSON (entities only) VA Partners, L.L.C. ______ 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* 3. SEC USE ONLY -----4. SOURCE OF FUNDS* 00* ______ 5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) 6. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware 7. SOLE VOTING POWER 0 NUMBER OF BENEFICIALLY 5.298 920+5 ______ OWNED BY EACH PERSON WITH 9. SOLE DISPOSITIVE POWER 10. SHARED DISPOSITIVE POWER 5,298,830** 11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,298,830** ______ 12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES 13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 8.8% 14. TYPE OF REPORTING PERSON 00 (LLC) ______ *See Item 3 **See Item 2 and 5 SCHEDULE 13D CUSIP NO. 00763M108 Page 5 of 19 1. NAME OF REPORTING PERSON/S.S. OR I.R.S. INDENTIFICATION NO. OF ABOVE PERSON (entities only) VA Partners III, L.L.C.

2.	CHECK THE APPRO	PRIAT	E BOX IF A MEMBER OF A GROUP*		[X]
3.	SEC USE ONLY				
4.	SOURCE OF FUNDS	*			
	00*				
5.	CHECK BOX IF DI PURSUANT TO ITE		URE OF LEGAL PROCEEDINGS IS REQUIRED d) or 2(e)		[]
6.	CITIZENSHIP OR	 PLACE	OF ORGANIZATION		
	Delaware				
		7.	SOLE VOTING POWER 0		
	NUMBER OF SHARES BENEFICIALLY		SHARED VOTING POWER 612,805**		
	OWNED BY EACH PERSON WITH		SOLE DISPOSITIVE POWER		
		10.	SHARED DISPOSITIVE POWER 612,805**		
11	. AGGREGATE AMOU	 NT BE	NEFICIALLY OWNED BY EACH REPORTING PERSON		
	612,805**				
12	. CHECK BOX IF T		GREGATE AMOUNT IN ROW (11) EXCLUDES		[]
13	. PERCENT OF CLA	SS RE	PRESENTED BY AMOUNT IN ROW (11)		
	1.0%				
14	. TYPE OF REPORT	ING P	ERSON		
	00 (LLC)				
	ee Item 3 See Item 2 and 5				
			SCHEDULE 13D		
CU	SIP NO. 00763M10		Pag	e 6 of	19
1.	NAME OF REPORTI		RSON/S.S. OR I.R.S. INDENTIFICATION NO. OF A	 30VE	
	ValueAct Capita				
		PRIAT	E BOX IF A MEMBER OF A GROUP*	(a) (b)	[X]
3	SEC USE ONLY				

4.	SOURCE OF FUNDS	*			
	00*				
5.	CHECK BOX IF DI PURSUANT TO ITE		URE OF LEGAL PROCEEDINGS IS REQUIRED d) or 2(e)		[]
6.	CITIZENSHIP OR	PLACE	OF ORGANIZATION		
	Delaware				
		7.	SOLE VOTING POWER		
	NUMBER OF SHARES BENEFICIALLY		SHARED VOTING POWER 5,911,635**		
	OWNED BY EACH PERSON WITH		SOLE DISPOSITIVE POWER 0		
		10.	SHARED DISPOSITIVE POWER 5,911,635**		
11	. AGGREGATE AMOU	NT BE	NEFICIALLY OWNED BY EACH REPORTING PERSO	ON	
	5,911,635**				
12	. CHECK BOX IF T CERTAIN SHARES		GREGATE AMOUNT IN ROW (11) EXCLUDES		[]
13	. PERCENT OF CLA	SS RE	PRESENTED BY AMOUNT IN ROW (11)		
	9.9%				
14	. TYPE OF REPORT	ING P	ERSON		
	PN				
	ee Item 3 See Item 2 and 5				
			SCHEDULE 13D		
CU:	 SIP NO. 00763M10	 8		 Page 7 of	 19
1.	NAME OF REPORTI PERSON (entitie	NG PE	RSON/S.S. OR I.R.S. INDENTIFICATION NO. y)		
	ValueAct Capita	l Man	agement, LLC		
2.			E BOX IF A MEMBER OF A GROUP*	(a)	 [X] []
3.	SEC USE ONLY				
4.	SOURCE OF FUNDS				
	00*				

5.	CHECK BOX IF DI PURSUANT TO ITE		URE OF LEGAL PROCEEDINGS IS REQUIRED d) or 2(e)	[]
6.	CITIZENSHIP OR	PLACE	OF ORGANIZATION	
	Delaware			
		7.	SOLE VOTING POWER 0	
	BENEFICIALLY			
	OWNED BY EACH PERSON WITH		SOLE DISPOSITIVE POWER 0	
		10.	SHARED DISPOSITIVE POWER 5,911,635**	
11	. AGGREGATE AMOU	NT BE	NEFICIALLY OWNED BY EACH REPORTING PERSON	
	5,911,635**			
12	. CHECK BOX IF T CERTAIN SHARES		GREGATE AMOUNT IN ROW (11) EXCLUDES	[]
13	. PERCENT OF CLA	SS RE	PRESENTED BY AMOUNT IN ROW (11)	
	9.9%			
14	. TYPE OF REPORT	ING P	ERSON	
	00 (LLC)			
	ee Item 3 See Item 2 and 5			
			SCHEDULE 13D	
CU.	 SIP NO. 00763M10	8		f 19
1.		NG PE	RSON/S.S. OR I.R.S. INDENTIFICATION NO. OF ABOVE	
	Jeffrey W. Ubbe			
2.	CHECK THE APPRO	PRIAT	d)	(X)
3.	SEC USE ONLY			
	SOURCE OF FUNDS			
	00*			
		SCLOS	URE OF LEGAL PROCEEDINGS IS REQUIRED	[]
6.	CITIZENSHIP OR	 PLACE	OF ORGANIZATION	

United States 7. SOLE VOTING POWER 0 ______ NUMBER OF 8. SHARED VOTING POWER BENEFICIALLY 5,911,635** OWNED BY EACH PERSON WITH 9. SOLE DISPOSITIVE POWER 10. SHARED DISPOSITIVE POWER 5,911,635** 11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,911,635** 12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES 13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 9.9% ______ 14. TYPE OF REPORTING PERSON ΙN ______ *See Item 3 **See Item 2 and 5 SCHEDULE 13D _____ CUSIP NO. 00763M108 Page 9 of 19 ______ 1. NAME OF REPORTING PERSON/S.S. OR I.R.S. INDENTIFICATION NO. OF ABOVE PERSON (entities only) George F. Hamel, Jr. 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [X] (b) [] 3. SEC USE ONLY 4. SOURCE OF FUNDS* _____ 5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) 6. CITIZENSHIP OR PLACE OF ORGANIZATION United States 7. SOLE VOTING POWER NUMBER OF -----

SHARES BENEFICIALLY			SHARED 5,911,	VOTING ,635**	POWER						
	OWNED BY EACH PERSON WITH		SOLE D		IVE POWE						
			SHAREI	D DISPOS ,635**	SITIVE F	POWER					
11.	. AGGREGATE AMOU	NT BE	NEFICIA	ALLY OWN	NED BY E	EACH RE	PORTING	PERSO	N		
	5,911,635**										
12.	CHECK BOX IF T	HE AG					EXCLUDE:	3			[]
13.	PERCENT OF CLA	SS RE	PRESENT	TED BY A	AMOUNT I	IN ROW					
	9.9%										
14.	TYPE OF REPORT	ING P	ERSON								
	IN										
	ee Item 3 See Item 2 and 5										
				SCHEI	DULE 13D)					
CUS	SIP NO. 00763M10	8							Page	10 of	£ 19
	NAME OF REPORTI PERSON (entitie			.S. OR 1	I.R.S. I	INDENTI	FICATIO	N NO. (OF ABO	VE	
	Peter H. Kamin										
2.	CHECK THE APPRO	PRIAT	E BOX	IF A MEN	MBER OF	A GROU	P*				[X] []
3.	SEC USE ONLY										
4.	SOURCE OF FUNDS	*									
	00*										
5.	CHECK BOX IF DI PURSUANT TO ITE						REQUIR			!	[]
6.	CITIZENSHIP OR	PLACE	OF OR	GANIZATI							
	United States										
	NUMBER OF	7.	SOLE V	VOTING E							
NUMBER OF SHARES BENEFICIALLY			5,911,	 D VOTING ,635**	G POWER						
	OWNED BY EACH PERSON WITH		SOLE I								

10. SHARED DISPOSITIVE POWER 5,911,635** 11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,911,635** _____ 12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES 13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) ______ 14. TYPE OF REPORTING PERSON ______ *See Item 3 **See Item 2 and 5 ______

CUSIP NO. 00763M108 Page 11 of 19

THE PURPOSE OF THIS AMENDMENT NO. 1 TO SCHEDULE 13D IS TO AMEND THE OWNERSHIP REPORTS OF THE REPORTING PERSONS. THE INFORMATION BELOW SUPPLEMENTS THE INFORMATION PREVIOUSLY PROVIDED.

Item 1. Security and Issuer

This Schedule 13D relates to the Common Stock, par value \$0.01 per share (the "Common Stock"), of Advanced Medical Optics, Inc., a Delaware corporation (the "Issuer"). The address of the principal executive offices of the Issuer is 1700 E. St. Andrew Place, Santa Ana, California 92705.

Item 2. Identity and Background

This statement is filed jointly by (a) ValueAct Capital Master Fund, L.P. ("ValueAct Master Fund"), (b) ValueAct Capital Master Fund III, L.P. ("ValueAct Master Fund III"), (c) VA Partners, LLC ("VA Partners"), (d) VA Partners III, LLC ("VA Partners III"), (e) ValueAct Capital Management, L.P. ("ValueAct Management L.P."), (f) ValueAct Capital Management, LLC ("ValueAct Management LLC"), (g) Jeffrey W. Ubben, (h) George F. Hamel, Jr. and (i) Peter H. Kamin (collectively, the "Reporting Persons").

ValueAct Master Fund and ValueAct Master Fund III are limited partnerships organized under the laws of the British Virgin Islands. Each has a principal business address of 435 Pacific Avenue, Fourth Floor, San Francisco, CA 94133.

VA Partners is a Delaware limited liability company, the principal business of which is to serve as the General Partner to ValueAct Master Fund. VA Partners III is a Delaware limited liability company, the principal business of which is to serve as the General Partner to ValueAct Master Fund III. Each has a principal business address of 435 Pacific Avenue, Fourth Floor, San Francisco, CA 94133.

ValueAct Management L.P. is a Delaware limited partnership which renders management services to ValueAct Master Fund and ValueAct Master Fund III. ValueAct Management LLC is a Delaware limited liability company, the

principal business of which is to serve as the General Partner to ValueAct Management L.P. Each has a principal business address of 435 Pacific Avenue, Fourth Floor, San Francisco, CA 94133.

- (a), (b) and (c). Messrs. Ubben, Hamel and Kamin are each managing members, principal owners and controlling persons of VA Partners, VA Partners III and ValueAct Management LLC, and such activities constitute their principal occupations. Such individuals are sometimes collectively referred to herein as the "Managing Members" or individually as a "Managing Member". Each Managing Member is a United States citizen and has a principal business address of 435 Pacific Avenue, Fourth Floor, San Francisco, CA 94133.
- (d) and (e). None of the entities or persons identified in this Item 2 has during the past five years been convicted of any criminal proceeding (excluding traffic violations or similar misdemeanors), nor been a party to a civil proceeding of a judicial or administrative body of competent judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

CUSIP NO. 00763M108

Page 12 of 19

Item 3. Source and Amount of Funds or Other Consideration

The source of funds used for the purchase of the Issuer's securities was the working capital of ValueAct Master Fund and ValueAct Master Fund III. The aggregate funds used by these Reporting Persons to make the purchases were \$48,106,402.07 and \$5,345,110.23.

Item 4. Purpose of Transaction

The Reporting Persons have acquired the Issuer's Common Stock for investment purposes, and such purchases have been made in the Reporting Persons' ordinary course of business.

In pursuing such investment purposes, the Reporting Persons may further purchase, hold, vote, trade, dispose or otherwise deal in the Common Stock at times, and in such manner, as they deem advisable to benefit from changes in market prices of such Common Stock, changes in the Issuer's operations, business strategy or prospects, or from sale or merger of the Issuer. To evaluate such alternatives, the Reporting Persons will routinely monitor the Issuer's operations, prospects, business development, management, competitive and strategic matters, capital structure, and prevailing market conditions, as well as alternative investment opportunities, liquidity requirements of the Reporting Persons and other investment considerations. Consistent with its investment research methods and evaluation criteria, the Reporting Persons may discuss such matters with management or directors of the Issuer, other shareholders, industry analysts, existing or potential strategic partners or competitors, investment and financing professionals, sources of credit and other investors. Such factors and discussions may materially affect, and result in, the Reporting Persons' modifying their ownership of Common Stock, exchanging information with the Issuer pursuant to appropriate confidentiality or similar agreements, proposing changes in the Issuer's operations, governance or capitalization, or in proposing one or more of the other actions described in subsections (a) through (j) of Item 4 of Schedule 13D.

The Reporting Persons reserve the right to formulate other plans and/or make other proposals, and take such actions with respect to their investment

in the Issuer, including any or all of the actions set forth in paragraphs (a) through (j) of Item 4 of Schedule 13D, or acquire additional Common Stock or dispose of all the Common Stock beneficially owned by them, in the public market or privately negotiated transactions. The Reporting Persons may at any time reconsider and change their plans or proposals relating to the foregoing.

Item 5. Interest in Securities of the Issuer

(a) and (b). Set forth below is the beneficial ownership of shares of Common Stock of the Issuer for each person named in Item 2. Shares reported as beneficially owned by ValueAct Master Fund and ValueAct Master Fund III are also reported as beneficially owned by (i) ValueAct Management L.P. as the manager of each such investment partnership, (ii) ValueAct Management LLC, as General Partner of ValueAct Management L.P. and (iii) the

CUSIP NO. 00763M108 Page 13 of 19

Managing Members as controlling persons of VA Partners, VA Partners III and ValueAct Management LLC. Shares reported as beneficially owned by ValueAct Master Fund are also reported as beneficially owned by VA Partners, as General Partner of ValueAct Master Fund. Shares reported as beneficially owned by ValueAct Master Fund III are also reported as beneficially owned by VA Partners III, as General Partner of ValueAct Master Fund III. VA Partners, VA Partners III, ValueAct Management LLC and the Managing Members also, directly or indirectly, may own interests in one or more than one of the partnerships from time to time. Unless otherwise indicated below, by reason of such relationships each of the ValueAct Master Fund and ValueAct Master Fund III is reported as having shared power to vote or to direct the vote, and shared power to dispose or direct the disposition of, such shares

As of the date hereof, ValueAct Master Fund is the beneficial owner of 5,298,830 shares of Common Stock, representing approximately 8.8% of the Issuer's outstanding Common Stock (which shares may also be deemed to be beneficially owned by VA Partners). As of the date hereof, ValueAct Master Fund III is the beneficial owner of 612,805 shares of Common Stock, representing 1.0% of the Issuer's outstanding Common Stock (which shares may also be deemed to be beneficially owned by VA Partners III).

of Common Stock, with VA Partners (only with respect to ValueAct Master Fund), VA Partners III (only with respect to ValueAct Master Fund III), ValueAct Management L.P., ValueAct Management LLC and the Managing Members.

ValueAct Management L.P., ValueAct Management LLC and the Managing Members may each be deemed the beneficial owner of an aggregate of 5,911,635 shares of Common Stock, representing approximately 9.9% of the Issuer's outstanding Common Stock.

All percentages set forth in this Schedule 13D are based upon the Issuer's reported 59,940,915 outstanding shares of Common Stock as reported in the Issuer's Form 10-Q for the quarterly period ended March $30,\ 2007$.

(c) Since the last filing the Reporting Persons purchased the following shares of Common Stock in the open market:

Reporting Person Trade Date Shares Price/Share

ValueAct Master Fu	ind 05/11/2007	90,000	41.03
	05/11/2007	25,741	40.98
	05/29/2007	540,000	34.87
	05/29/2007	90,000	34.88
	05/30/2007	225,000	34.21
	05/30/2007	225,000	34.23
	05/31/2007	52,560	34.73
	05/31/2007	28,260	34.74
	06/01/2007	90,000	34.96

CUSIP NO. 00763M108 Page 14 of 19

		~1	- I (a)
Reporting Person	Trade Date	Shares	Price/Share
ValueAct Master Fund III	05/11/2007	2 , 859	40.98
	05/11/2007	10,000	41.03
	05/29/2007	10,000	34.88
	05/29/2007	60,000	34.87
	05/30/2007	25,000	34.23
	05/30/2007	25,000	34.21
	05/31/2007	5,840	34.73
	05/31/2007	3,140	34.74
	06/01/2007	10,000	34.96

(d) and (e) Not applicable.

CUSIP NO. 00763M108 Page 15 of 19

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

Other than as described elsewhere in this Report and as previously reported, the Reporting Persons have no understandings, arrangements, relationships or contracts relating to the Issuer's Common Stock which are required to be described hereunder.

Item 7. Material to Be Filed as Exhibits

(1) Joint Filing Agreement.

CUSIP NO. 00763M108 Page 16 of 19

SIGNATURE

After reasonable inquiry and to the best of his knowledge and belief, the undersigned certifies that the information set forth in this

statement is true, complete and correct.

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below on this Schedule 13D hereby constitutes and appoints Jeffrey W. Ubben, George F. Hamel, Jr. and Peter H. Kamin, and each of them, with full power to act without the other, his or its true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or it and in his or its name, place and stead, in any and all capacities (until revoked in writing) to sign any and all amendments to this Schedule 13D, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-infact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary fully to all intents and purposes as he or it might or could do in person, thereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

ValueAct Capital Master Fund L.P., by VA Partners, L.L.C., its General Partner By: /s/ George F. Hamel, Jr. _____ Dated: June 5, 2007 George F. Hamel, Jr., Managing Member ValueAct Capital Master Fund III L.P., by VA Partners III, L.L.C., its General Partner By: /s/ George F. Hamel, Jr. Dated: June 5, 2007 George F. Hamel, Jr., Managing Member VA Partners, L.L.C. By: /s/ George F. Hamel, Jr. _____ Dated: June 5, 2007 George F. Hamel, Jr., Managing Member VA Partners III, L.L.C. By: /s/ George F. Hamel, Jr. Dated: June 5, 2007 George F. Hamel, Jr., Managing Member

CUSIP NO. 00763M108 Page 17 of 19

Dated: June 5, 2007

ValueAct Capital Management, L.P., by ValueAct Capital Management, LLC its General Partner

By: /s/ George F. Hamel, Jr.

George F. Hamel, Jr., Managing Member

14

		ValueAct Capital Management, LLC
		By: /s/ George F. Hamel, Jr.
Dated:	June 5, 2007	George F. Hamel, Jr., Managing Member
		By: /s/ Jeffrey W. Ubben
Dated:	June 5, 2007	Jeffrey W. Ubben, Managing Member
		By: /s/ George F. Hamel, Jr.
Dated:	June 5, 2007	George F. Hamel, Jr., Managing Member
		By: /s/ Peter H. Kamin
Dated:	June 5, 2007	Peter H. Kamin, Managing Member
CUSIP N	O. 00763M108	Page 18 of 19
		JOINT FILING UNDERTAKING hereby agree that the Schedule 13D filed herewith eto) relating to the Common Stock of Advanced Medical
(and an Optics, Securit	y amendments there Inc. is being files and Exchange (hereby agree that the Schedule 13D filed herewith eto) relating to the Common Stock of Advanced Medical led jointly on behalf of each of them with the Commission pursuant to Section 13(d) of the of 1934, as amended.
(and an Optics, Securit	y amendments there Inc. is being files and Exchange (hereby agree that the Schedule 13D filed herewith eto) relating to the Common Stock of Advanced Medical led jointly on behalf of each of them with the Commission pursuant to Section 13(d) of the
(and an Optics, Securit	y amendments there Inc. is being files and Exchange (hereby agree that the Schedule 13D filed herewith eto) relating to the Common Stock of Advanced Medical led jointly on behalf of each of them with the Commission pursuant to Section 13(d) of the of 1934, as amended. ValueAct Capital Master Fund L.P., by
(and an Optics, Securit Securit	y amendments there Inc. is being files and Exchange (hereby agree that the Schedule 13D filed herewith eto) relating to the Common Stock of Advanced Medical led jointly on behalf of each of them with the Commission pursuant to Section 13(d) of the of 1934, as amended. ValueAct Capital Master Fund L.P., by VA Partners, L.L.C., its General Partner
(and an Optics, Securit Securit	y amendments there Inc. is being fi ies and Exchange (ies Exchange Act (hereby agree that the Schedule 13D filed herewith eto) relating to the Common Stock of Advanced Medical led jointly on behalf of each of them with the Commission pursuant to Section 13(d) of the of 1934, as amended. ValueAct Capital Master Fund L.P., by VA Partners, L.L.C., its General Partner By: /s/ George F. Hamel, Jr.
(and an Optics, Securit Securit	y amendments there Inc. is being fi ies and Exchange (ies Exchange Act (hereby agree that the Schedule 13D filed herewith eto) relating to the Common Stock of Advanced Medical led jointly on behalf of each of them with the Commission pursuant to Section 13(d) of the of 1934, as amended. ValueAct Capital Master Fund L.P., by VA Partners, L.L.C., its General Partner By: /s/ George F. Hamel, Jr. George F. Hamel, Jr., Managing Member ValueAct Capital Master Fund III L.P., by
(and an Optics, Securit Securit Dated:	y amendments there Inc. is being fi ies and Exchange (ies Exchange Act (hereby agree that the Schedule 13D filed herewith eto) relating to the Common Stock of Advanced Medical led jointly on behalf of each of them with the Commission pursuant to Section 13(d) of the of 1934, as amended. ValueAct Capital Master Fund L.P., by VA Partners, L.L.C., its General Partner By: /s/ George F. Hamel, Jr. George F. Hamel, Jr., Managing Member ValueAct Capital Master Fund III L.P., by VA Partners III, L.L.C., its General Partner
(and an Optics, Securit Securit Dated:	June 5, 2007	hereby agree that the Schedule 13D filed herewith eto) relating to the Common Stock of Advanced Medical led jointly on behalf of each of them with the Commission pursuant to Section 13(d) of the of 1934, as amended. ValueAct Capital Master Fund L.P., by VA Partners, L.L.C., its General Partner By: /s/ George F. Hamel, Jr. George F. Hamel, Jr., Managing Member ValueAct Capital Master Fund III L.P., by VA Partners III, L.L.C., its General Partner By: /s/ George F. Hamel, Jr.
(and an Optics, Securit Securit Dated:	June 5, 2007	hereby agree that the Schedule 13D filed herewith eto) relating to the Common Stock of Advanced Medical led jointly on behalf of each of them with the Commission pursuant to Section 13(d) of the of 1934, as amended. ValueAct Capital Master Fund L.P., by VA Partners, L.L.C., its General Partner By: /s/ George F. Hamel, Jr. George F. Hamel, Jr., Managing Member ValueAct Capital Master Fund III L.P., by VA Partners III, L.L.C., its General Partner By: /s/ George F. Hamel, Jr. George F. Hamel, Jr., Managing Member
(and an Optics, Securit Securit Dated:	June 5, 2007	hereby agree that the Schedule 13D filed herewith eto) relating to the Common Stock of Advanced Medical led jointly on behalf of each of them with the Commission pursuant to Section 13(d) of the of 1934, as amended. ValueAct Capital Master Fund L.P., by VA Partners, L.L.C., its General Partner By: /s/ George F. Hamel, Jr. George F. Hamel, Jr., Managing Member ValueAct Capital Master Fund III L.P., by VA Partners III, L.L.C., its General Partner By: /s/ George F. Hamel, Jr. George F. Hamel, Jr., Managing Member VA Partners, L.L.C.
(and an Optics, Securit Securit Dated:	June 5, 2007	hereby agree that the Schedule 13D filed herewith eto) relating to the Common Stock of Advanced Medical led jointly on behalf of each of them with the Commission pursuant to Section 13(d) of the of 1934, as amended. ValueAct Capital Master Fund L.P., by VA Partners, L.L.C., its General Partner By: /s/ George F. Hamel, Jr. George F. Hamel, Jr., Managing Member ValueAct Capital Master Fund III L.P., by VA Partners III, L.L.C., its General Partner By: /s/ George F. Hamel, Jr. George F. Hamel, Jr., Managing Member VA Partners, L.L.C. By: /s/ George F. Hamel, Jr. George F. Hamel, Jr., Managing Member

-	-	
Dated: June 5, 20	George F. Hamel, Jr., Managing Member	
	ValueAct Capital Management, L.P., by, ValueAct Capital Management, LLC its General Partner	
	By: /s/ George F. Hamel, Jr.	
Dated: June 5, 20	George F. Hamel, Jr., Managing Member	
	ValueAct Capital Management, LLC	
	By: /s/ George F. Hamel, Jr.	
Dated: June 5, 20	George F. Hamel, Jr., Managing Member	
CUSIP NO. 00763M108	Page 19 of 1	
	By: /s/ Jeffrey W. Ubben	
Dated: June 5, 20		
	By: /s/ George F. Hamel, Jr.	
Dated: June 5, 20		
	By: /s/ Peter H. Kamin	
Dated: June 5, 20		